ORKA - MoonLake rebounds despite downgrades prompted by trial setback
2025-09-30 13:34:03 ET
More on MoonLake Immunotherapeutics
- MoonLake: From 'Best-In-Class' Hopes To Approvability Debate (Rating Downgrade)
- MoonLake Immunotherapeutics (MLTX) RND Day Conference Call (Transcript)
- MoonLake Immunotherapeutics (MLTX) RND Day Conference Presentation - Slideshow
- MoonLake plunges after mixed results from skin disease trial
- Goldman's 48 potential M&A candidates